# TMC435-TiDP16-C119 - A Study Comparing 2 New Capsule Formulations of TMC435 to an Established Capsule Formulation and Evaluating the Respective Blood Levels of TMC435 Following Single Dose Administration

> **NCT01134718** · PHASE1 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 24 (actual)

## Conditions studied

- Hepatitis C Virus

## Interventions

- **DRUG:** TMC435 (G006)
- **DRUG:** TMC435 (F021)
- **DRUG:** TMC435 (G007)

## Key facts

- **NCT ID:** NCT01134718
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2013-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01134718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01134718, "TMC435-TiDP16-C119 - A Study Comparing 2 New Capsule Formulations of TMC435 to an Established Capsule Formulation and Evaluating the Respective Blood Levels of TMC435 Following Single Dose Administration". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT01134718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*